STOCK TITAN

Perimeter Medical Imaging Ai (PYNKF) Stock News

PYNKF OTC

Welcome to our dedicated page for Perimeter Medical Imaging Ai news (Ticker: PYNKF), a resource for investors and traders seeking the latest updates and insights on Perimeter Medical Imaging Ai stock.

Perimeter Medical Imaging AI develops real-time optical coherence tomography imaging systems and artificial-intelligence tools for cancer surgery. The company’s Claire OCT+AI device has FDA premarket approval for intraoperative breast cancer margin assessment, while its S-Series OCT platform provides ultra-high-resolution cross-sectional visualization of excised tissue.

Company news commonly covers FDA regulatory milestones, product demonstrations, commercialization activity, clinical and technology updates, operating and financial results, investor conference presentations, and capital-structure actions such as private placements, warrants, and stock-option matters.

Rhea-AI Summary
Perimeter Medical Imaging AI has launched the OCT-Tissue Surveillance Registry, a database aimed at collecting thousands of surgical procedure images and data using their imaging technology. The registry will support future product development and enhance their AI deep-learning model. The company's S-Series OCT technology provides real-time, ultra-high resolution visualization of tissue specimens during surgery. Their next-generation B-Series OCT with ImgAssist AI 2.0, currently under FDA review, integrates AI to help detect suspicious tissue during breast-conserving surgery. Dr. Jennifer Tittensor, who has used the technology in over 120 surgeries, highlighted its value in assessing margins in real-time. The registry will help gather diverse patient data to improve AI algorithm training, potentially leading to more personalized care and reduced need for second surgeries.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.12%
Tags
AI
-
Rhea-AI Summary

Perimeter Medical Imaging AI (TSXV: PINK, OTCQX: PYNKF) has partnered with Intermountain Health, the largest nonprofit health system in the Intermountain West, through a Development Support Agreement (DSA). The collaboration aims to study the value of Perimeter's Optical Coherence Tomography (OCT) technology and gather data for AI algorithm development.

The initial study will analyze reoperation rates and healthcare costs for breast-conserving surgery (BCS) patients at select hospitals. The partnership will support Perimeter's FDA PMA approval process for their AI-enabled OCT system and potential expansion into other tissue types beyond breast surgery.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.16%
Tags
partnership AI
-
Rhea-AI Summary

Perimeter Medical Imaging AI (TSX-V: PINK) (OTCQX: PYNKF), a commercial-stage medical technology company, has scheduled its first quarter 2025 financial results announcement for Tuesday, May 13, 2025, after market close. The company will host a conference call and webcast at 5:00 pm Eastern Time to discuss the results and provide a corporate update. Investors can access the call via 1-800-717-1738 (Canada/US) or 1-646-307-1865 (International). The webcast will be available live and archived on Perimeter's website in the Investors section under "News/Events".

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.2%
Tags
conferences earnings AI
Rhea-AI Summary
Perimeter Medical Imaging AI presented detailed results from their pivotal trial of B-Series OCT with ImgAssist AI 2.0 for breast cancer surgery margin assessment at ASBrS 2025. The trial met its primary endpoint with statistically significant results (p=0.0050), demonstrating super-superiority compared to standard care. Key findings include: - Among 206 patients, the system correctly detected residual disease in 40% of cases (14/35 patients) after standard care - Completely cleared residual disease in 20% of additional patients - Achieved 88.1% overall margin accuracy - Required minimal additional tissue removal (only 3.8% of total volume) - Benefited 26 patients clinically, including 6 cases where the system detected disease missed by both standard care and histopathology The company has submitted a Premarket Approval application to the FDA in March 2025 for use during breast-conserving surgeries.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.84%
Tags
AI
-
Rhea-AI Summary

Perimeter Medical Imaging AI announced that HonorHealth, a major healthcare system in Phoenix and Scottsdale, has become Arizona's first to implement their S-Series OCT technology for visualizing tissue margins during surgery.

The groundbreaking Optical Coherence Tomography technology offers superior resolution compared to traditional imaging methods, enabling visualization at the cellular level. It creates 3D images with 10 times the resolution of ultrasound and X-ray, and 100 times that of MRI, helping surgeons make real-time decisions during procedures.

Key advantages include:

  • 2mm resolution optimization for tissue microstructures
  • Real-time visualization of surgical margins
  • FDA clearance for general tissue imaging since 2021

This deployment represents a significant expansion of Perimeter's commercial presence in the Southwest, potentially reducing the need for follow-up surgeries that typically result from waiting up to 10 days for traditional pathology results.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.25%
Tags
none
-
Rhea-AI Summary

Perimeter Medical Imaging AI (TSXV: PINK) (OTCQX: PYNKF), a commercial-stage medical technology company, has announced its upcoming participation at the 2025 Bloom Burton & Co. Healthcare Investor Conference.

Key details:

  • Event Date: Monday, May 5, 2025
  • Time: 9:30 a.m. Eastern Time
  • Location: Metro Toronto Convention Centre

The company's management will deliver a business update presentation at the conference. For those unable to attend in person, the presentation will be available through a live broadcast and will also be archived on the company's website. Interested parties can access the presentation recording in the "News/Events" section under the Investors tab of Perimeter's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.06%
Tags
conferences AI
Rhea-AI Summary

Perimeter Medical Imaging AI (PYNKF) reported its Q4 and full-year 2024 financial results, highlighting significant commercial growth. The company achieved nine new S-Series OCT system placements in 2024, up from three in 2023, with Q4-2024 revenues increasing 303% year-over-year to $293,000.

The company's pivotal study for its next-generation B-Series OCT with ImgAssist AI 2.0 met its primary endpoint, demonstrating statistically significant reduction in patients with residual cancer during breast-conserving surgeries. Perimeter recently submitted a Premarket Approval (PMA) application to the FDA for this technology.

Financial highlights for FY2024 include:

  • Revenue of $846,000, up 110% from 2023
  • Operating expenses of $19.4 million
  • Net loss of $13.4 million ($0.19 per share)
  • Cash position of $6.2 million as of December 31, 2024
  • Additional $2.0 million CPRIT grant receivable

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.93%
Tags
conferences earnings AI
-
Rhea-AI Summary

Perimeter Medical Imaging AI (TSXV: PINK) (OTCQX: PYNKF), a commercial-stage medical technology company, has announced it will release its fourth quarter and full year 2024 financial results after market close on March 26, 2025. The company's management team will subsequently host a webcast and conference call to discuss the results and provide a corporate update. The call will be broadcast live and archived on the company's website in the Investors section under 'News/Events'.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.43%
Tags
conferences earnings AI
-
Rhea-AI Summary

Perimeter Medical Imaging AI (TSXV: PINK, OTCQX: PYNKF) announced that Covenant Health Fort Sanders Regional has become the first hospital in Tennessee to implement their S-Series OCT (Optical Coherence Tomography) technology for visualizing tissue margins during surgery.

The S-Series OCT technology provides real-time margin visualization with resolution 10 times higher than ultrasound and X-ray, and 100 times more powerful than MRI. It can visualize tissue microstructures down to 2mm in ducts, vessels, and glands, potentially reducing the need for follow-up surgeries by eliminating the traditional 10-day wait for pathology results.

Dr. Ana Wilson, a surgical oncologist at Covenant Health Fort Sanders Regional, highlighted how the technology enables patient-specific surgical decisions in real-time. The implementation represents a significant milestone in Perimeter's nationwide expansion strategy and aligns with their goal of improving surgical outcomes while reducing healthcare costs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.49%
Tags
AI
Rhea-AI Summary

Perimeter Medical Imaging AI (TSXV: PINK, OTCQX: PYNKF) announced that its pivotal trial results for the B-Series OCT with ImgAssist AI 2.0 will be presented at the 2025 American Society of Breast Surgeons Annual Meeting. The trial, focused on breast-conserving surgeries, met its primary endpoint with a statistically significant reduction in patients with residual cancer during surgery (p-value = 0.0050).

The detailed results are under embargo until May 1, 2025, 1:00 pm PST, and will be presented by Dr. Alastair Thompson, the trial's Primary Principal Investigator from Baylor College of Medicine. The full abstract will be published in the Annals of Surgical Oncology.

Following positive topline results reported in November 2024, Perimeter plans to submit its FDA premarket approval (PMA) application in early 2025 to market the AI-enabled OCT system in the United States. The technology provides real-time, high-resolution visualization of margins in the operating room.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.85%
Tags
AI

FAQ

What is the current stock price of Perimeter Medical Imaging Ai (PYNKF)?

The current stock price of Perimeter Medical Imaging Ai (PYNKF) is $0.19904 as of August 28, 2026.

What is the market cap of Perimeter Medical Imaging Ai (PYNKF)?

The market cap of Perimeter Medical Imaging Ai (PYNKF) is approximately 30.0M.